目的 探究降脂通便膠囊聯(lián)合莫沙必利治療便秘型腸易激綜合征患者的臨床效果。方法 納入2023年3月—2024年3月首都醫(yī)科大學(xué)附屬北京康復(fù)醫(yī)院收治的便秘型腸易激綜合征患者60例，采用隨機(jī)數(shù)字表法分為對(duì)照組（n=30）與治療組（n=30）。對(duì)照組餐前口服枸櫞酸莫沙必利片5 mg/次，每天3次；治療組在此基礎(chǔ)上加服降脂通便膠囊0.5 g/次，每天2次。兩組均持續(xù)治療4周。通過(guò)對(duì)比兩組患者的臨床效果，統(tǒng)計(jì)分析治療前后中醫(yī)證候評(píng)分、腸易激綜合征生活質(zhì)量量表（IBS-QOL）評(píng)分、血清5-羥色胺（5-HT）、血管活性腸肽（VIP）和神經(jīng)肽Y（NPY）、肛管靜息壓和最大縮榨壓水平。結(jié)果 治療組總有效率（93.33%）顯著高于對(duì)照組（70.00%）（P＜0.05）。經(jīng)治療，治療組患者中醫(yī)證候評(píng)分大幅度下降，而IBS-QOL評(píng)分明顯上升（P＜0.05），且治療組患者評(píng)分改善程度明顯好于對(duì)照組（P＜0.05）。治療后，兩組患者血清5-HT、NPY水平較治療前顯著提升，而VIP水平顯著降低（P＜0.05），且治療組患者各指標(biāo)改善明顯好于對(duì)照組（P＜0.05）。經(jīng)治療，兩組肛管靜息壓和最大縮榨壓水平較治療前明顯升高（P＜0.05），且治療組直腸動(dòng)力學(xué)指標(biāo)改善程度均勝于對(duì)照組（P＜0.05）。結(jié)論 降脂通便膠囊聯(lián)合莫沙必利可協(xié)同改善便秘型腸易激綜合征患者的臨床癥狀、生活質(zhì)量及肛腸動(dòng)力學(xué)參數(shù)，同時(shí)有效調(diào)節(jié)胃腸激素平衡。

Objective To explore the therapeutic effect of Jiangzhi Tongbian Capsules combined with mosapride in treatment of constipated irritable bowel syndrome. Methods Patients (60 cases) with constipated irritable bowel syndrome in Beijing Rehabilitation Hospital Affiliated to Capital Medical University from March 2023 to March 2024 were randomly divided into control (30 cases) and treatment (30 cases) group. Patients in the control group were po administered with Mosapride Citrate Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Jiangzhi Tongbian Capsules on the basis of the control group, 0.5 g/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, and the TCM syndrome score and IBS-QOL score, serum 5-HT, VIP, and NPY levels, resting pressure and maximum squeeze pressure of anal canalin two groups before and after treatment were compared. Results After treatment, there was a statistically significant difference in the clinical total effective rate between the control group (70.00%) and the treatment group (93.33%, P < 0.05). After treatment, the TCM syndrome score in the treatment group was significantly decreased, while the IBS-QOL score was significantly increased (P < 0.05), and the improvement of the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the serum 5-HT and NPY levels in two groups were significantly increased compared with before treatment, while the VIP level was significantly decreased (P < 0.05), and the improvement of each index in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the resting pressure and maximum squeeze pressure levels of anal canal in two groups were significantly higher than before treatment (P < 0.05), and the improvement of rectal dynamics indicators in the treatment group was better than that in the control group (P < 0.05). Conclusion Jiangzhi Tongbian Capsules combined with moxapride can synergically improve the clinical symptoms, quality of life and anorectal dynamic parameters of patients with constipated irritable bowel syndrome, and can effectively regulate gastrointestinal hormone balance.

R975